Real-World data on iloprost for tough lung condition
NCT ID NCT07478094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 72 adults with pulmonary hypertension caused by chronic lung diseases, like interstitial lung disease, who were treated with inhaled iloprost in routine care. Researchers tracked changes in their risk levels over time using a standard scoring model. The goal was to gather real-world evidence on how well this treatment works in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- iloprost (inhaled)
- What this could lead to
- If results are positive, this could support using inhaled iloprost more widely for lung disease-related pulmonary hypertension.
- What could go wrong
- This is a small, observational study without a control group, so it cannot prove iloprost works. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
72 people
The number who actually took part.
- Started
-
May 2026
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with pulmonary hypertension due to chronic lung disease and/or hypoxia (group 3 pulmonary hypertension) receiving care at a specialized pulmonary circulation outpatient clinic. The study population includes patients with underlying interstitial lung disease or chronic obstructive pulmonary disease who were treated with inhaled iloprost as part of routine clinical practice. The cohort represents a real-world population followed longitudinally using data available from medical records, without additional study-specific procedures or patient contact.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Diagnosis of group 3 pulmonary hypertension confirmed by right heart catheterization, defined as mean pulmonary artery pressure \>20 mmHg, pulmonary artery wedge pressure ≤15 mmHg, and pulmonary vascular resistance \>2 Wood units * Presence of documented underlying chronic lung disease (e.g., interstitial lung disease confirmed by high-resolution computed tomography with restrictive pattern on pulmonary function testing, or chronic obstructive pulmonary disease) * Use of inhaled iloprost for a minimum of 3 months, documented in medical records * Availability of baseline clinical data (at initiation of inhaled iloprost) and at least one follow-up assessment Exclusion Criteria: * Pulmonary hypertension from other clinical groups (Groups 1, 2, 4, or 5) as the predominant diagnosis * Insufficient clinical information in medical records to allow characterization or longitudinal assessment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary hypertension due to lung diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
São Paulo, São Paulo, 05403-900, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.